Open AccessRisk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial
Author(s) -
Dorothy Sebikari,
Mona Farhad,
Terry Fenton,
Maxensia Owor,
Jeffrey S. A. Stringer,
Min Qin,
Nahida Chakhtoura,
H. Benjamin,
Friday Saidi,
Neetal Nevrekar,
Avy Violari,
Tsungai Chipato,
James McIntyre,
Dhayendre Moodley,
Taha E. Taha,
Gerhard Theron,
Mary Glenn Fowler
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002072
Subject(s) - medicine , regimen , low birth weight , adverse effect , obstetrics , pregnancy , emtricitabine , premature birth , small for gestational age , gestational age , randomized controlled trial , pediatrics , viral load , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , genetics , biology
In the multicountry PROMISE 1077BF/1077FF trial, the risk of low birth weight (LBW; <2500 g) and preterm delivery (PTD; <37 weeks) was significantly higher among women initiating a protease inhibitor-based antiretroviral treatment (ART) regimen than those receiving ZDV alone. Among those assigned to a protease inhibitor regimen, tenofovir/emtricitabine was associated with the more severe outcomes of very LBW (<1500 g) and very PTD (<34 weeks) compared with zidovudine/lamivudine.